Long-form guides, side-effect deep-dives, and protocol comparisons for men’s health. No paid posts. No “transform your life” copy. We write what we’d want to read before making a treatment decision — for ourselves or someone in our family. Browse by category, search by keyword, or read everything we’ve published.
Retatrutide produces meaningfully greater weight loss than tirzepatide — roughly 24–28% of body weight versus 20–22% — and the mechanism explains why. Tirzepatide hits two receptors; retatrutide hits three.
Eliminating added sugar for 30 days triggers measurable changes in insulin signaling, liver fat, cardiovascular markers, and testosterone — and most of them start within the first week. This isn't a detox myth; it's well-supported physiology.
Tirzepatide and semaglutide are the two strongest options for men with high BMI right now — and the data gap between them and older agents like liraglutide is wide enough that the choice is rarely close.
GLP-1 receptor agonists like Wegovy and Zepbound dominate the weight-loss conversation, but several other peptide classes are producing meaningful — sometimes dramatic — results for men who can't tolerate, access, or fully respond to semaglutide or tirzepatide.
Six months on retatrutide produces weight loss in the 13–17% range at doses of 8–12 mg weekly — results that outpace what most researchers see with semaglutide or tirzepatide at comparable timepoints.
Switching from Ozempic to Rybelsus is not a simple formulation swap — at currently available doses, you're trading predictable injection-level efficacy for needle-free convenience at a meaningful cost to weight-loss depth. Here's what the clinical data actually show.
Saxenda delivers meaningful weight loss — roughly 8% of body weight over 56 weeks — but semaglutide-based therapy, whether as Ozempic off-label or Wegovy at full 2.4 mg dosing, consistently outperforms it, producing 10–15% losses in major trials.
Ozempic and Wegovy both contain semaglutide, but calling them interchangeable misses what actually separates them in practice: dose ceiling, approved indication, and the clinical experience that follows from both.
Zepbound and Mounjaro contain identical molecules — tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly — but exist as separate branded products because the U.S. regulatory and insurance systems treat diabetes drugs and obesity drugs as categorically different.
Tirzepatide produces meaningfully greater average weight loss than semaglutide — roughly 20–22% of body weight versus 15% — but semaglutide carries more mature cardiovascular outcome data that matters for men with established heart disease.
Ready to start a protocol?
Connect with vetted online providers for TRT, GLP-1, ED treatment, and more.
